Carboplatin-liposomes (CPL) in immunodeficient mice: Improved antitumor activity for breast carcinomas and stimulation of hematopoiesis

Abstract

Carboplatin-liposomes (CPL) have been shown to possess a strong stimulatory activity on the hematopoiesis in immunocompetent mice. As we were interested in studying this pharmacological characteristic in parallel with any antitumour effects which might be expected for the encapsulated cytostatic, we used a panel of six human breast carcinomas xenotransplanted to nude mice. The antitumor activity as well as the hematopoietic effects of the vesicles were studied in comparison to, and in combination with, the free drug. Carboplatin was encapsulated into reverse phase evaporation vesicles (REV) and injected i.p. as a single dose of 75 mg kg-1 into tumor-free and breast-carcinoma-bearing animals, respectively. Following a single application of CPL in nude mice, a significant increase of the WBC numbers to about three times for that of the normal level could be observed over a period of at least 28 days. The elevation was due to an increase in both circulating granulocytes and lymphocytes. The peripheral effect was accompanied by a relative decrease of spleen cellularity, while the number of bone marrow cells was hardly affected. There was no influence detectable on circulating blood cells in SCID mice. However, a rather high toxicity of CPL for this immunodeficient mouse strain was noticed. In the panel of breast carcinomas used, free carboplatin and CPL displayed a different pattern of therapeutic efficiencies. In four of the five tumor models tested, a combination of the free with the liposomal drug showed a significant inhibition of tumor growth while effectively preventing a drug-induced leukopenia.(ABSTRACT TRUNCATED AT 250 WORDS)

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

“…Liposomes are able to reduce toxic side-effects of anti-cancer agents while maintaining or enhancing their therapeutic effects [7,9,18,22,23], e.g. by improvement of traffic through inter-and intracellular barriers [24][25][26].…”

Liposomes in Cancer Therapy: How Did We Start and Where Are We Now

“…This method is based on the formation of an emulsion of an aqueous phase (containing the drug) and an organic phase (containing the lipid), followed by the evaporation of the organic solvent, and the formation of an aqueous suspension containing the assembled liposomes [ 83 , 84 ]. Examples of drugs that have been encapsulated using this method include the anti-Alzheimer drug tacrine hydrochloride [ 85 ], the anti-cancer drug doxorubicin [ 86 ], and carboplatin [ 87 ].…”

Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro

“…Thus, an encapsulation of the drug (or of derivatives of this hormone antagonist) into nanospheres [14] or liposomes can change the transport concerning time and distribution in a beneficial way. The potential of liposomes to reduce toxic side effects of anti-cancer agents and to maintain or even to enhance their therapeutic effects [15][16][17][18][19], for instance, by a modified transport trough inter-and intracellular barriers is well known [15].…”